- Home
- OSTX
as 10-04-2024 4:00pm EST
Stocks
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 86.5M | IPO Year: | 2024 |
| Target Price: | $21.00 | AVG Volume (30 days): | 61.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.51 - $4.90 | Next Earning Date: | 11-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 9900.00% |
Latest OS THERAPIES INCORPORATED News
OSTX Breaking Stock News: Dive into OSTX Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
Business Wire
22 days ago
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
ACCESSWIRE
24 days ago
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Business Wire
a month ago
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
Business Wire
a month ago
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
Business Wire
a month ago
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
Business Wire
a month ago
OS Therapies Clarifies CUSIP of Common Stock
Business Wire
2 months ago
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
Compare OSTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OSTX OS THERAPIES INCORPORATED - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.